JGC
IONS icon

J. Goldman & Co’s Ionis Pharmaceuticals IONS Stock Holding History

J. Goldman & Co’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-190,000
Closed -$7.51M – 539
2025
Q2 		$7.51M Buy
+190,000
New +$6.22M 0.18% 157
2024
Q4 		– Sell
-90,800
Closed -$3.64M – 541
2024
Q3 		$3.64M Sell
90,800
-54,200
-37% -$2.52M 0.1% 193
2024
Q2 		$6.91M Buy
+145,000
New +$5.95M 0.2% 141

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

J. Goldman & Co's IONS Position: Q1 2026 in Review

J. Goldman & Co increased its Ionis Pharmaceuticals (IONS) stake by 248% in Q1 2026, buying an estimated $13.2M and bringing the position to 235,260 shares worth $17.7M. The position accounts for 0.51% of the portfolio, ranked #47.

J. Goldman & Co first reported a position in IONS in Q1 2024 and has held it in 9 quarters since. The position peaked at $24.4M in Q3 2024. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • J. Goldman & Co held 235,260 shares of Ionis Pharmaceuticals worth $17.7M as of Q1 2026.
  • J. Goldman & Co bought 167,621 Ionis Pharmaceuticals shares in Q1 2026, an estimated $13.2M.
  • Ionis Pharmaceuticals made up 0.51% of J. Goldman & Co's portfolio in Q1 2026, its #47 holding.
  • J. Goldman & Co first reported a position in Ionis Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • J. Goldman & Co's Ionis Pharmaceuticals position peaked at $24.4M in Q3 2024.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.